SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • December 28th, 2017 • Endonovo Therapeutics, Inc. • Pharmaceutical preparations • Nevada
This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of December 21, 2017, by and between Endonovo Therapeutics, Inc., a Delaware corporation, with headquarters located at 6320 Canoga Avenue, 15th Floor, Woodland Hills, CA 91367, (the “Company”), and EAGLE EQUITIES, LLC, a Nevada limited liability company, with its address at 91 Shelton Ave, Suite 107, New Haven, CT 06511 (the “Buyer”).
6% Senior Convertible NOTEConvertible Security Agreement • July 15th, 2016 • Endonovo Therapeutics, Inc. • Pharmaceutical preparations • New York
THIS 6% SENIORCONVERTIBLE NOTE is one of a series of duly authorized and validly issued 6% Senior Convertible Notes issued at a 5.5% original issue discount by Endonovo Therapeutics, Inc., a Delaware corporation (the “Company”) (this note, the “Note” and, collectively with the other notes of such series, the “Notes”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • January 3rd, 2019 • Endonovo Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
Registration Rights Agreement (the “Agreement”), dated as of December 31, 2018, by and between ENDONOVO THERAPEUTICS, INC., a corporation organized under the laws of Delaware, USA (the “Company”), and Azure Capital, a Massachusetts Corporation (the “Investor”).
INVESTMENT AGREEMENTInvestment Agreement • January 3rd, 2019 • Endonovo Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
INVESTMENT AGREEMENT (this “AGREEMENT”), dated as of December 31, 2018 by and between ENDONOVO THERAPEUTICS, INC., a Delaware corporation (the “Company”), and Azure Capital, a Massachusetts Corporation (the “Investor”).
EQUITY PURCHASE AGREEMENTEquity Purchase Agreement • January 21st, 2015 • Endonovo Therapeutics, Inc. • Pharmaceutical preparations • California
THIS EQUITY PURCHASE AGREEMENT entered into as of the 19th day of January, 2015 (this "AGREEMENT"), by and between KODIAK CAPITAL GROUP, LLC, a Delaware limited liability company ("INVESTOR"), and ENDONOVO THERAPEUTICS, INC., a Delaware corporation (the "COMPANY").
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • January 21st, 2015 • Endonovo Therapeutics, Inc. • Pharmaceutical preparations • California
This Registration Rights Agreement ("Agreement"), dated January 19, 2015, is made by and between ENDONOVO THERAPEUTICS, INC., a Delaware corporation ("Company"), and KODIAK CAPITAL GROUP, LLC a Delaware limited liability company (the "Investor").
AMENDED AND RESTATED SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • October 6th, 2016 • Endonovo Therapeutics, Inc. • Pharmaceutical preparations • New York
This Amended and Restated Securities Purchase Agreement (this “Agreement”) is dated as of September 30, 2016, between Endonovo Therapeutics, Inc. a Delaware corporation (the “Company”), and Bellridge Capital, LP (the “Purchaser”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • July 15th, 2016 • Endonovo Therapeutics, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of July 8, 2016 by and between Endonovo Therapeutics, Inc., a Delaware corporation (the “Company”) and Bellridge LP (the “Purchaser). Capitalized terms used in this Agreement and not otherwise defined shall have the meanings ascribed to them in Article 1.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • July 15th, 2016 • Endonovo Therapeutics, Inc. • Pharmaceutical preparations • New York
THIS REGISTRATION RIGHTS AGREEMENT, is by and between Endonovo Therapeutics, Inc., a Delaware corporation (the “Company”), and Bellridge Capital LP(the “Holder”), and is made pursuant to that certain Securities Purchase Agreement between the Company and the Holder, dated as of the date hereof (the “Purchase Agreement”).
Re: Finder’s Fee AgreementFinder’s Fee Agreement • May 10th, 2022 • Endonovo Therapeutics, Inc. • Pharmaceutical preparations • New York
As you know, Endonovo Therapeutics, Inc. (the “Issuer”), has expressed an interest in obtaining private equity or debt capital for various purposes. This letter agreement (“Agreement”) sets forth the terms and conditions upon which J.H. Darbie & Co., Inc. (“Darbie”), will introduce the Issuer to third-party investors (each, an “Introduced Party”).
DEBT PURCHASE AGREEMENTDebt Purchase Agreement • April 17th, 2017 • Endonovo Therapeutics, Inc. • Pharmaceutical preparations • New York
This Debt Purchase Agreement (the “Agreement”) made as of this 7th day of April 2017, by and between Eagle Equities, LLC (the “Buyer or Investor”) and Bellridge Capital LLC (the “Seller”).
SECURITY AGREEMENTSecurity Agreement • December 28th, 2017 • Endonovo Therapeutics, Inc. • Pharmaceutical preparations • California
This SECURITY AGREEMENT (the “Agreement”), dated and effective as of the 21day of December, 2018, is made by Endonovo Therapeutics, Inc. (“Debtor”) having a notice address of 6320 Canoga Avenue, 15th Floor, Woodland Hills, CA 91367 in favor of EAGLE EQUITIES, LLC, a Nevada limited liability company, with its address at 91 Shelton Ave, Suite 107, New Haven, CT 06511 (“Secured Party”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • May 26th, 2020 • Endonovo Therapeutics, Inc. • Pharmaceutical preparations • New York
THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of May 18, 2020 (the “Execution Date”), is entered into by and between Endonovo Therapeutics, Inc., a Delaware corporation (the “Company”) and Cavalry Fund I LP, a Delaware limited partnership (the “Investor”). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in that certain Equity Line Purchase Agreement by and between the parties hereto, dated as of the Execution Date (as amended, restated, supplemented or otherwise modified from time to time, the “Purchase Agreement”).
EXCHANGE AGREEMENTExchange Agreement • December 7th, 2018 • Endonovo Therapeutics, Inc. • Pharmaceutical preparations
THIS EXCHANGE AGREEMENT (the “Agreement”) is as of November 30, 2018, by and among Endonovo Therapeutics, Inc. a Delaware corporation (the “Company”), and Eagle Equities, LLC (the “Holder”).
SUBSCRIPTION AGREEMENTSubscription Agreement • May 10th, 2022 • Endonovo Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS INVESTMENT INVOLVES A HIGH DEGREE OF RISK. THIS INVESTMENT IS SUITABLE ONLY FOR PERSONS WHO CAN BEAR THE ECONOMIC RISK FOR AN INDEFINITE PERIOD OF TIME AND WHO CAN AFFORD TO LOSE THEIR ENTIRE INVESTMENT. FURTHERMORE, INVESTORS MUST UNDERSTAND THAT SUCH INVESTMENT IS ILLIQUID AND IS EXPECTED TO CONTINUE TO BE ILLIQUID FOR AN INDEFINITE PERIOD OF TIME. NO PUBLIC MARKET EXISTS FOR THE SECURITIES, AND NO PUBLIC MARKET IS EXPECTED TO DEVELOP FOLLOWING THIS OFFERING.
EQUITY LINE PURCHASE AGREEMENTEquity Line Purchase Agreement • May 26th, 2020 • Endonovo Therapeutics, Inc. • Pharmaceutical preparations • New York
THIS EQUITY LINE PURCHASE AGREEMENT (the “Agreement”), is entered into as of May 18, 2020 (the “Execution Date”), by and between Endonovo Therapeutics, Inc., a Delaware corporation (the “Company”), and Cavalry Fund I LP, a Delaware limited partnership (the “Investor”).
CONSULTING AGREEMENTConsulting Agreement • June 13th, 2016 • Endonovo Therapeutics, Inc. • Pharmaceutical preparations • Nevada
Regal Consulting, a limited liability company organized under the laws of the state of Delaware (the “Consultant”), and Endonovo Therapeutics Inc., a corporation organized under the laws of the State of Delaware, with its principal place of business 6320 Canoga Ave 15th Floor Woodland Hills, CA 91367 (“Client”).
PRIVATE & CONFIDENTIALLetter of Intent (Loi) • July 11th, 2016 • Endonovo Therapeutics, Inc. • Pharmaceutical preparations • California
This binding letter agreement (“LOI”), which has been approved by the Boards of Directors of each of the parties hereto and is subject only to completion of Definitive Documents and required Shareholder approvals outlines the intentions of Endonovo Therapeutics, Inc. (“Buyer”) with respect to the purchase (“Transaction”) of all of the outstanding Common and Preferred Shares (the “Stock”) of the Company on terms as follows:
PEMF HOLDINGS, LLC Langhorne, PA 19047Letter of Intent • March 29th, 2023 • Endonovo Therapeutics, Inc. • Electromedical & electrotherapeutic apparatus
This Letter of Intent (“LOI”) is a firm commitment to purchase all the common shares of stock of SofPulse, Inc. (the “Company”), a Delaware corporation and a wholly owned subsidiary of Endonovo Therapeutics, Inc., a Delaware corporation (“ENDV”). Based on these agreed to terms the purchase the shares of the Company shall be completed with completion of and full execution of a Definitive Purchase Agreement. This document outlines the commitment by PEMF HOLDINGS, LLC., a Delaware limited liability company (“Buyer”) with respect to the purchase (“Transaction”) of all of the shares of the Company from ENDV which is also sometimes referred to as the “Seller” on the following terms:
SHARE EXCHANGE AGREEMENTShare Exchange Agreement • March 21st, 2012 • Hanover Portfolio Acquisitions, Inc. • Services-consumer credit reporting, collection agencies • California
This Share Exchange Agreement ("Agreement"), dated as of March 14, 2012, is made by, and between, Hanover Portfolio Acquisitions, Inc., a Delaware corporation (“Parent”), IP Resources International, Inc., a Nevada corporation (“Company”), and the shareholders of the Company that are signatory hereto or who sign a Shareholder Joinder to the Share Exchange Agreement in the form of Exhibit “A” hereto (each a “Shareholder” and, jointly, the “Shareholders”). Each of the parties to this Agreement is individually referred to herein as a “Party” and collectively as the “Parties.”
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • April 17th, 2017 • Endonovo Therapeutics, Inc. • Pharmaceutical preparations • Nevada
This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of April 7, 2017, by and between Endonovo Therapeutics, Inc., a Delaware corporation, with headquarters located at 6320 Canoga Avenue, 15th Floor, Woodland Hills, CA 91367, (the “Company”), and EAGLE EQUITIES, LLC, a Nevada limited liability company, with its address at 91 Shelton Ave, Suite 107, New Haven, CT 06511 (the “Buyer”).
AGREEMENT AND PLAN OF MERGER OF HANOVER ASSET MANAGEMENT, INC (a California corporation) ANDMerger Agreement • September 22nd, 2011 • Hanover Portfolio Acquisitions, Inc.
This Agreement and Plan of Merger, dated as of June 15, 2011 (the " Agreement "), is made by and between Hanover Asset Management, Inc., a California corporation (" Hanover California"), and Hanover Capital Management, Inc., a Delaware corporation and wholly-owned subsidiary of Hanover California ("Hanover Delaware "). Hanover California and Hanover Delaware are sometimes referred to herein as the (" Constituent Corporations .")
Broker-Dealer AgreementBroker-Dealer Agreement • February 11th, 2022 • Endonovo Therapeutics, Inc. • Pharmaceutical preparations
This agreement (together with exhibits and schedules, the “Agreement”) is entered into by and between Endonovo Therapeutics, Inc. (“Client”), a Delaware Corporation, and Dalmore Group, LLC., a New York Limited Liability Company (“Dalmore”). Client and Dalmore agree to be bound by the terms of this Agreement, effective as of February 3, 2022 (the “Effective Date”):
SALES AND MARKETING AGREEMENTSales and Marketing Agreement • August 14th, 2018 • Endonovo Therapeutics, Inc. • Pharmaceutical preparations • California
This Sales and Marketing Agreement (the “Agreement”) is entered into August 10, 2018 (“Effective Date”) by and between Endonovo Therapeutics, Inc. (OTCQB: ENDV), a Delaware corporation having its principal business address of 6320 Canoga Avenue, 15th Floor, Woodland Hills, CA 91367 (“ENDONOVO”) and MAGNIANT, LLC, a California limited liability company with offices at 7343 Bolero St Carlsbad CA 92009 (“MAGNIANT”). Each of MAGNIANT and ENDONOVO shall sometimes be referred to as a “Party” and collectively, as the “Parties”. This Agreement supersedes and replaces in their entirety, without prejudice, any and all other agreements or contracts between the parties, excluding the Non-Disclosure Agreement signed by the Parties.
ASSET PURCHASE AGREEMENTAsset Purchase Agreement • September 27th, 2022 • Endonovo Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This Asset Purchase Agreement (the “Agreement”), is entered into and effective as of September 26, 2022 (the “Signing Date”) by and among Endonovo Therapeutics, Inc., a Delaware corporation (the “Buyer”), Western Star Concrete, LLC, a Texas limited liability company (“Western Star” and/or “Seller”) and Gabriel Mark Salmons (“Owner,” and collectively with Seller , the “Seller Parties”). Buyer, Seller and Owner are referred to individually herein as a “Party” and collectively herein as the “Parties.”
NOTE MODIFICATION AND FOREBAREANCE AGREEMENTNote Modification and Forbearance Agreement • May 26th, 2020 • Endonovo Therapeutics, Inc. • Pharmaceutical preparations • New York
Note Modification and Forbearance Agreement, dated as of May 20, 2020, by and among Endonovo Therapeutics, Inc., a Delaware corporation, with an address of 6320 Canoga Avenue - 15th Floor, Woodland Hills, CA 91367 (“ENDV”) and the party set forth on the signature page hereto (the “Lender”);
ASSET PURCHASE AGREEMENTAsset Purchase Agreement • November 19th, 2013 • Hanover Portfolio Acquisitions, Inc. • Services-consumer credit reporting, collection agencies • Texas
This ASSET PURCHASE AGREEMENT (this “Agreement”) is entered into as of November 16, 2013 (“Effective Date”), by and between Hanover Portfolio Acquisitions, Inc., with an office at 6320 Canoga Ave. 15th Floor, Woodland Hills, CA 91367 (“Purchaser”), WeHealAnimals, Inc., with an address at 1700 Rivercrest Dr. #1205 ,Sugar Land, TX 77478 (“Company”) and Dr. Donnie Rudd, sole shareholder, with an address at 1700 Rivercrest Dr. #1205 ,Sugar Land, TX 77478 (“Shareholder”). The parties hereby agree as follows:
ASSET PURCHASE AGREEMENTAsset Purchase Agreement • December 4th, 2023 • Endonovo Therapeutics, Inc. • Electromedical & electrotherapeutic apparatus • Delaware
This Asset Purchase Agreement (the “Agreement”), is entered into and effective as of December 3, 2023 (the “Signing Date”) by and among SofPulse, Inc., a Delaware corporation (the “Buyer”), Endonovo Therapeutics, Inc., a Delaware corporation (“ENDV” and/or “Seller”). Buyer and Seller are referred to individually herein as a “Party” and collectively herein as the “Parties.”
AMENDMENT TO AGREEMENTSales and Strategic Partnership Agreement • January 3rd, 2024 • Endonovo Therapeutics, Inc. • Electromedical & electrotherapeutic apparatus
THIS AMENDMENT AGREEMENT, dated as of December 29, 2023 (this “Amendment”), by and between Evermed Medical Enterprise Ltd (the “EVERMED”) and Endonovo Therapeutics, Inc. (“ENDONOVO”), amends the Sales and Strategic Partnership Agreement (the “Agreement”)
